SCHEMBL1973408

SCHEMBL1973408

O=c1c(O)c(-c2ccc(O)c(O)c2)oc2c(O)cc(CCCCCCCCCCCCO)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 9/20 0.52
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 3/20 0.48
ALOX15 P16050 3/20 0.48
KMT2A Q03164 3/20 0.48
SLCO2B1 O94956 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
APEX1 P27695 2/20 0.48
AMY1A P0DUB6 2/20 0.48
TP53 P04637 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
ALOX12 P18054 2/20 0.48
MAPK1 P28482 2/20 0.48
RECQL P46063 2/20 0.48
HSD17B10 Q99714 2/20 0.48
GLA P06280 1/20 0.48
FBP1 P09467 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974384 1.00 CDK2 (0.52) CDK2KDM4EMEN1MAPTALOX15
SCHEMBL1421468 0.84 MEN1 (0.57) CDK2KDM4EMEN1MAPTALOX15
SCHEMBL1974001 0.84 CDK2 (0.52) CDK2KDM4EMEN1MAPTALOX15
SCHEMBL1975543 0.84 CDK2 (0.52) CDK2KDM4EMEN1MAPTALOX15
SCHEMBL12557441 0.84 MEN1 (0.57) CDK2KDM4EMEN1MAPTALOX15
SCHEMBL1976272 0.81 MEN1 (0.53) KDM4EMEN1MAPTALOX15KMT2A
SCHEMBL1973909 0.81 MEN1 (0.53) KDM4EMEN1MAPTALOX15KMT2A
SCHEMBL1975837 0.78 ABCG2 (0.53) KDM4EMEN1MAPTALOX15KMT2A
SCHEMBL1974843 0.78 ABCG2 (0.53) KDM4EMEN1MAPTALOX15KMT2A
SCHEMBL1974544 0.77 MEN1 (0.56) CDK2KDM4EMEN1MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA CDK2 664/4885KDM4E 2608/4885MEN1 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.